Alnylam Pharmaceuticals (ALNY) Short-term Investments (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Short-term Investments for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short-term Investments fell 8.26% year-over-year to $1.6 billion; the trailing twelve-month figure through Jun 2026 stood at $1.6 billion (down 8.26% YoY), and the FY2025 full-year result was $1.3 billion, down 27.25% from the prior year.
• Short-term Investments rose to $1.6 billion in Q2 2026 per ALNY's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $1.7 billion in Q2 2025 and bottomed at $1.2 billion in Q3 2022.
• Historically, Short-term Investments has averaged $1.5 billion across 5 years, with a median of $1.6 billion in 2022.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments soared 36.52% in 2022, then retreated 27.25% in 2025.
• Over 5 years, Short-term Investments stood at $1.3 billion in 2022, then gained by 24.47% to $1.6 billion in 2023, then grew by 6.46% to $1.7 billion in 2024, then declined by 27.25% to $1.3 billion in 2025, then gained by 27.86% to $1.6 billion in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $1.6 billion, $1.3 billion, and $1.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.